<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=utf-8">
<meta name="Generator" content="Microsoft Word 15 (filtered medium)">
<style><!--
/* Font Definitions */
@font-face
{font-family:Wingdings;
panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Palatino;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0in;
margin-bottom:.0001pt;
font-size:12.0pt;
font-family:"Calibri",sans-serif;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:#0563C1;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:#954F72;
text-decoration:underline;}
p.msonormal0, li.msonormal0, div.msonormal0
{mso-style-name:msonormal;
mso-margin-top-alt:auto;
margin-right:0in;
mso-margin-bottom-alt:auto;
margin-left:0in;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
span.EmailStyle18
{mso-style-type:personal;
font-family:Palatino;
color:windowtext;
font-weight:normal;
font-style:normal;}
span.apple-converted-space
{mso-style-name:apple-converted-space;}
span.EmailStyle20
{mso-style-type:personal;
font-family:"Calibri",sans-serif;
color:#1F497D;}
span.EmailStyle21
{mso-style-type:personal;
font-family:"Calibri",sans-serif;
color:#1F497D;}
span.EmailStyle22
{mso-style-type:personal-reply;
font-family:"Calibri",sans-serif;
color:#1F497D;}
.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;}
@page WordSection1
{size:8.5in 11.0in;
margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
{page:WordSection1;}
/* List Definitions */
@list l0
{mso-list-id:1481265398;
mso-list-template-ids:1754567432;}
@list l0:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l0:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1
{mso-list-id:1587034382;
mso-list-template-ids:-72576198;}
@list l1:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level2
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
ol
{margin-bottom:0in;}
ul
{margin-bottom:0in;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]-->
</head>
<body lang="EN-US" link="#0563C1" vlink="#954F72">
<div class="WordSection1">
<p class="MsoNormal"><span style="font-family:Palatino;color:black"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__grants.nih.gov_grants_guide_pa-2Dfiles_PAR-2D19-2D264.html&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=yfjd2v2b-gC4rZRPOo5ianSftOjHtB9yl2TAsupVr_U&s=5DOU-22_H7n35uZ0KXblq-ihx7tZQQEbVd6MuakRTq4&e=" target="_blank">Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Aggressive Cancer (R01
Clinical Trial Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:black">This Funding Opportunity Announcement (FOA) will support the development of state-of-the-art projects that include imaging, biomarkers, digital pathomic and other -omic integration strategies
for improving current approaches for the earliest detection of premetastatic aggressive cancer as well as identifying precancerous lesions that will subsequently demonstrate an aggressive phenotype. This FOA specifically attempts to address and improve diagnostic
uncertainty in clinical decisions in a technology agnostic manner by improving sensitivity and specificity of applied tests. N-dimensional co-registered, cross-correlated imaging results integrated with multiplexed biomarker data and digital pathomics using
analytic strategies such as artificial intelligence and virtual reality visualization for improving discovery are encouraged. The projects supported by this FOA will collectively participate in the existing Consortium for Imaging and Biomarkers (CIB) Research
Program. The goals of the CIB are to: (1) improve diagnostic performance by developing methodology for the early identification of lethal cancer versus non-lethal disease, (2) to minimize/better manage overdiagnosis and (3) to reduce false positives and false
negatives.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:black">Due July 10, 2019; December 10, 2019; July 10, 2020; December 10, 2020; July 9, 2021; and December 10, 2021.
</span></b><b><span style="font-family:Palatino;color:red">Med-RA deadline to receive draft documents for July 2019 deadline: June 24.</span></b><span style="font-family:Palatino;color:black"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:black"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:black"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__professional.diabetes.org_meetings_core-2Dprogram-23custom-2Dcollapse-2D3-2Dminoritypostdoctoral-2Dfellowship-2Dpmf&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=yfjd2v2b-gC4rZRPOo5ianSftOjHtB9yl2TAsupVr_U&s=nDNdA6H06Tb5Hn0UnSrSMyaod54eU_4TpxOk3E8WvfQ&e=" target="_blank">American Diabetes Association: Core Research Program
Awards</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:black">The American Diabetes Association’s Core Research Program funds research with novel and innovative hypotheses in any area relevant to the etiology or pathophysiology of diabetes and its complications
that hold significant promise for advancing the prevention, cure or treatment of diabetes. Basic, clinical, translational and epidemiological or health services research approaches are encouraged.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:black"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:black">Research Awards</span></b><span style="font-family:Palatino;color:black"><br>
Innovative Basic Science<br>
Innovative Clinical or Translational Science<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:black"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:black">Development Awards</span></b><span style="font-family:Palatino;color:black"><br>
Junior Faculty Development<br>
Minority Junior Faculty Development<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:black"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:black">Training Awards</span></b><span style="font-family:Palatino;color:black"><br>
Postdoctoral Fellowship<br>
Minority Postdoctoral Fellowship<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:black"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:black">Applications for all awards due July 15, 2019.
</span></b><b><span style="font-family:Palatino;color:red">Med-RA deadline to receive draft documents: June 27.</span></b><span style="color:black"><o:p></o:p></span></p>
<p class="MsoNormal" style="font-variant-caps: normal;orphans: auto;text-align:start;widows: auto;-webkit-text-size-adjust: auto;-webkit-text-stroke-width: 0px;word-spacing:0px">
<span style="font-family:Palatino;color:black"> </span><span style="color:black"><o:p></o:p></span></p>
<p class="MsoNormal" style="font-variant-caps: normal;orphans: auto;text-align:start;widows: auto;-webkit-text-size-adjust: auto;-webkit-text-stroke-width: 0px;word-spacing:0px">
<span style="font-family:Palatino;color:black"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__www.aacr.org_Funding_Pages_Funding-2DDetail.aspx-3FItemID-3D71&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=yfjd2v2b-gC4rZRPOo5ianSftOjHtB9yl2TAsupVr_U&s=otqd18dK8WP0WOpic1_OgwLimaq3CJfP-lOhLaSFevU&e=" target="_blank">American Association for Cancer Research: – Johnson & Johnson Lung Cancer Innovation Science Grants</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:black">The American Association for Cancer Research – Johnson & Johnson Lung Cancer Innovation Science Grants program is a joint effort to address the need for promoting and supporting collaborative
cancer research in areas that include digital therapeutics and smoking cessation, as well as biomarkers/behavioral phenotyping that bolster understanding of how lung cancer can be successfully intercepted. To that end, a grant of $1 million over three years
will be awarded to a multi-institutional team in support of a new idea and/or innovative approach that has direct application and relevance to lung cancer prevention and interception. The proposed research should be translational in nature and include a clinical
component with an endpoint relevant to improving the detection or treatment of lung cancer. Priority areas of interest include clinical trials that identify unique high-risk patients for lung cancer and demonstrate sustained efficacy through the measurement
of both quit rates as well as disease-related biomarkers; and clinical trials that identify digital therapeutics focused on smoking avoidance for first-time smokers or for former smokers (these therapeutics may consider the impact of social engagement, gaming,
and other content relevant for a population at a risk of starting or resuming the smoking habit). The inclusion of a strategic plan for clinical confirmation of the digital therapeutic study is recommended.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:black">Due July 19, 2019.
</span></b><b><span style="font-family:Palatino;color:red">Med-RA deadline to receive draft documents: July 8.</span></b><span style="color:black"><o:p></o:p></span></p>
<p class="MsoNormal" style="font-variant-caps: normal;orphans: auto;text-align:start;widows: auto;-webkit-text-size-adjust: auto;-webkit-text-stroke-width: 0px;word-spacing:0px">
<span style="font-family:Palatino;color:black"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:black"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__grants.nih.gov_grants_guide_pa-2Dfiles_PAR-2D19-2D258.html&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=yfjd2v2b-gC4rZRPOo5ianSftOjHtB9yl2TAsupVr_U&s=QbKie2s3eeft6Gb68afPGxjf4HGlp-lGUOH3QFxVe-0&e=" target="_blank">NIDA Research Education Program for Clinical Researchers and Clinicians (R25 Clinical Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:black">The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NIDA R25 program is to support educational activities
that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs. This FOA is intended to support
<b>research education activities that enhance the knowledge of substance use (SU) and substance use disorder (SUD) research</b>. The program is intended for those in clinically focused careers and/or
<b>those training for careers as clinicians/health service providers, clinical researchers, or optimally a combination of the two</b>. This mechanism may not be used to support non-research-related clinical training.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:black">To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on:<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="color:black;mso-list:l0 level1 lfo3"><b><i><span style="font-family:Palatino">Courses for Skills Development:</span></i></b><span style="font-family:Palatino"> Activities may include advanced courses in a specific discipline or
research area, clinical procedures for research, neuroethics in clinical research, specialized research techniques, or other topics that would complement and enhance the research experiences proposed. Additionally, career development seminars and workshops
such as grant writing, manuscript preparation, and building a successful career path are encouraged.<o:p></o:p></span></li><li class="MsoNormal" style="color:black;mso-list:l0 level1 lfo3"><b><i><span style="font-family:Palatino">Research Experiences:
</span></i></b><span style="font-family:Palatino">Activities include hands-on exposure to research for undergraduate students and research experiences for graduate and medical students, postdoctorates, and/or early career faculty. The nature of research experiences
should be tailored to the needs and career level of participants. It is expected that mentoring will be provided in conjunction with planned research experiences.<o:p></o:p></span></li></ul>
<p class="MsoNormal"><span style="font-family:Palatino;color:black">The proposed research education programs must include both courses for skills development and research experiences; however, primary emphasis should be given to research experiences. Courses
for skills development should be proposed in conjunction with research experiences.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:black">Due July 22, 2019; July 22, 2020; and July 22, 2021.
</span></b><b><span style="font-family:Palatino;color:red">Med-RA deadline to receive draft documents for 2019 deadline: July 8.</span></b><span style="font-family:Palatino;color:black"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:black"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:black">HLA and KIR Region Genomics in Immune-Mediated Diseases (U01 / U19 Clinical Trial Not Allowed)<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:black"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__grants.nih.gov_grants_guide_rfa-2Dfiles_RFA-2DAI-2D19-2D041.html&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=yfjd2v2b-gC4rZRPOo5ianSftOjHtB9yl2TAsupVr_U&s=H6Hgk84oB1Aofkts97cwwAz9PO3I8SwtFVzi1TQ7sk0&e=" target="_blank">U01</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:black"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__grants.nih.gov_grants_guide_rfa-2Dfiles_RFA-2DAI-2D19-2D044.html&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=yfjd2v2b-gC4rZRPOo5ianSftOjHtB9yl2TAsupVr_U&s=WGkQkUlxtUrSu-9MaUTf7TXWfo4qWM4FfAYobMzskh0&e=" target="_blank">U19</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:black">The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications from investigators to participate in the HLA and KIR Region Genomics in Immune Mediated Diseases Consortium
(HLARGC). This cooperative research group supports projects defining the association between variations in the human leukocyte antigen (HLA), also known as the Major Histocompatibility Complex (MHC), and natural killer cell immunoglobulin-like receptor (KIR)
genetic regions and immune-mediated diseases, including outcomes following cell, tissue, and organ transplantation.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:black">Due September 4, 2019.
</span></b><b><span style="font-family:Palatino;color:red">Med-RA deadline to receive draft documents: August 21.</span></b><span style="font-family:Palatino;color:black"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:black"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:black">To search for additional funding opportunities, please visit </span><span style="color:black"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV6980C-DCl-AxzFLHMVYQ&e="><span style="font-family:Palatino;color:#954F72">CoM’s
unofficial funding opportunities blog</span></a></span></b><b><span style="font-family:Palatino;color:black">.</span></b><span style="color:black"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
</div>
</body>
</html>